UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
DERMATOLOGY & AESTHETICS

AbbVie

A

AbbVie

Dermatology & AestheticsNorth Chicago, United States
Visit Website

About AbbVie

AbbVie built one of the world's best-selling medicines in Humira, the anti-inflammatory biologic that reshaped the treatment of rheumatoid arthritis, psoriasis and inflammatory bowel disease and held the position of the globe's top-revenue drug for over a decade. Spun out of Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie is listed on the New York Stock Exchange under the ticker ABBV and ranks among the largest pharmaceutical companies by market capitalisation.

Immunology & Oncology Leadership

Immunology remains the company's core franchise, anchored by Humira and its successors Skyrizi (risankizumab) and Rinvoq (upadacitinib), both of which have grown rapidly across multiple approved indications including plaque psoriasis, Crohn's disease and ulcerative colitis. In oncology, AbbVie markets Imbruvica (ibrutinib), a BTK inhibitor developed in partnership with Janssen, and Venclexta (venetoclax), a BCL-2 inhibitor co-developed with Roche, both indicated for certain blood cancers including chronic lymphocytic leukaemia.

Neuroscience & Aesthetics Portfolio

AbbVie significantly broadened its therapeutic reach with the 2020 acquisition of Allergan, one of the largest pharmaceutical mergers in history. That transaction brought the company Botox (both therapeutic and cosmetic), the migraine portfolio including Ubrelvy and Qulipta, and a range of medical aesthetics products. The neuroscience division now spans migraine prevention, movement disorders and psychiatry, with further pipeline candidates in Parkinson's disease and mood disorders. The aesthetics business, marketed under the Allergan Aesthetics brand, positions AbbVie as a leader in a segment beyond traditional pharmaceuticals.

With operations spanning more than 70 countries and a global workforce numbering in the tens of thousands, AbbVie invests heavily in research and development, maintaining a broad pipeline across immunology, oncology, neuroscience and eye care. The company is a constituent of the S&P 500 and is widely followed for its progressive dividend policy.

Further information is available at abbvie.com.

Similar Companies

More in Dermatology & Aesthetics

A

Almirall

Founded in Barcelona in 1943, Almirall has evolved from a general pharmaceutical manufacturer into one of Europe's leading speciality pharma companies with an exclusive focus on dermatology. Listed on the Barcelona Stock Exchange (ticker: ALM), the company directs its entire research, development and commercial infrastructure towards skin disease, giving it a depth of therapeutic expertise rarely matched by larger, more diversified pharmaceutical groups. Dermatology Portfolio and Pipeline Almirall's marketed portfolio spans several significant skin conditions. Ilumetri (tildrakizumab) targets moderate-to-severe plaque psoriasis via selective IL-23 inhibition. Klisyri (tirbanibulin) addresses actinic keratosis, a precancerous skin condition with high prevalence in sun-exposed populations. Seysara (sarecycline) provides a narrow-spectrum antibiotic option for acne, while Skilarence (dimethyl fumarate) is indicated for adults with moderate-to-severe plaque psoriasis. The company continues to build its pipeline through internal R&D and strategic licensing agreements, with atopic dermatitis representing a key area of expansion. Almirall operates commercially across Europe and North America, working directly with dermatologists, healthcare systems and specialist pharmacy channels. Its medical affairs and market access teams support reimbursement and formulary positioning in individual national markets. The company's singular therapeutic focus has positioned it as a recognised partner for academics, patient advocacy groups and clinical networks operating within the dermatology community. Further information is available at almirall.com.

View profile
A

argenx

argenx built its reputation on a single, unusually productive starting point: the immune systems of llamas and other camelids, which produce a class of antibodies that proved to be a powerful foundation for engineering next-generation immunology medicines. From that scientific premise, the Belgian-American company has grown into one of the most closely watched names in immunology drug development, with a commercial product, VYVGART (efgartigimod alfa), approved in multiple markets for the treatment of generalised myasthenia gravis. Founded in 2008 and headquartered in Ghent, Belgium, with significant operations in the United States and Japan, argenx is listed on Nasdaq (ARGX) and on Euronext Brussels, reflecting its transatlantic scope. The company's pipeline is centred on FcRn biology, targeting the neonatal Fc receptor to reduce disease-causing IgG antibodies in a range of serious autoimmune conditions. This mechanism underpins efgartigimod in several additional indications under investigation, as well as other early-stage programmes in the portfolio. The company operates with a focused autoimmune disease strategy rather than pursuing broad therapeutic diversification, concentrating resources on conditions where dysregulated IgG antibodies drive pathology. Target areas include neuromuscular disease, haematology, and dermatology, among others under active clinical investigation. Further information is available at argenx.com.

View profile
A

Alcyomics

Founded in 2007 as a spinout from Newcastle University, Alcyomics develops and delivers human in vitro assays that enable pharmaceutical, biotechnology, chemical, and cosmetic companies to detect adverse immune reactions early in the development process, reducing both risk and cost before clinical stages are reached. The company's scientific foundation was built by Professor Anne Dickinson, whose three decades of research into transplantation and graft-versus-host disease at Newcastle University produced skin-based assay methodologies that have demonstrated over 80% correlation with clinical outcomes. That research led directly to Alcyomics' flagship technology: the patented Skimune platform, a highly sensitive human in vitro skin assay that uses matched skin and blood from the same donor to predict immune responses to small and large molecule drugs, monoclonal antibodies, cellular therapies, and cosmetic compounds. Building on the core Skimune test, Alcyomics has expanded its model portfolio to include Skimune 3D, a high-throughput full-thickness skin equivalent developed in collaboration with REPROCELL, as well as an innervated skin model for neurotoxicity assessment and a bioprinted osteo-arthritic joint model aimed at transforming drug discovery for osteoarthritis. The company operates from state-of-the-art laboratories within The Biosphere in Newcastle upon Tyne, serving a global client base that includes top-tier pharmaceutical organisations. Further information is available at alcyomics.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy